These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 30334503)
21. Fix the antibiotics pipeline. Cooper MA; Shlaes D Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175 [No Abstract] [Full Text] [Related]
22. Pharmaceuticals and medical devices: FDA oversight. ; Berry MD Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845 [No Abstract] [Full Text] [Related]
23. Re-engineering drug discovery and development. FitzGerald GA LDI Issue Brief; 2011 Oct; 17(2):1-4. PubMed ID: 22049582 [TBL] [Abstract][Full Text] [Related]
24. Is the priority review voucher program stimulating new drug development for tropical diseases? Kerr KW; Henry TC; Miller KL PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006695. PubMed ID: 30092022 [TBL] [Abstract][Full Text] [Related]
26. A cheat sheet to navigate the complex maze of exclusivities in the United States. Peng B; Tomas MC Pharm Pat Anal; 2014 Jul; 3(4):339-43. PubMed ID: 25291306 [No Abstract] [Full Text] [Related]
27. PDUFA V goes back to basics. Mullard A Nat Rev Drug Discov; 2012 Aug; 11(8):586-8. PubMed ID: 22850772 [No Abstract] [Full Text] [Related]
28. Congress, the FDA, and the fair development of new medications for children. McKinney RE Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299 [No Abstract] [Full Text] [Related]
29. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
30. The 21st Century Cures Act--Will It Take Us Back in Time? Avorn J; Kesselheim AS N Engl J Med; 2015 Jun; 372(26):2473-5. PubMed ID: 26039522 [No Abstract] [Full Text] [Related]
32. Hunting for New Drugs with AI. Freedman DH Nature; 2019 Dec; 576(7787):S49-S53. PubMed ID: 31853074 [No Abstract] [Full Text] [Related]
33. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers. Soehnge H Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584 [No Abstract] [Full Text] [Related]
35. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars. Gitter DM Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759 [No Abstract] [Full Text] [Related]
36. Recent developments help the defense of drug companies in 10b-5 cases. Salpeter AN; Hutchins H Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711 [No Abstract] [Full Text] [Related]
37. The FDA and "privatization"--the drug approval process. Rutherford EM Food Drug Law J; 1995; 50 Spec():203-25. PubMed ID: 10343044 [No Abstract] [Full Text] [Related]
38. Old drugs, new uses: solving a Hatch-Waxman patent predicament. McPhie DC Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929 [No Abstract] [Full Text] [Related]
39. Realizing two-tiered innovation policy through drug regulation. Ridgway WE Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807 [No Abstract] [Full Text] [Related]